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Background. Migraine is prevalent in young patients and a frequent stroke mimic. To distinguish stroke mimics from true stroke
can be difficult, and there is a possibility of misdiagnosing a stroke as a migrainous attack in patients with migraine. We aimed to
investigate if a history of migraine affects the rate of thrombolytic therapy in young stroke patients.Methods. All patients below 50
years of age admitted in the period 2006–2013 to the Bergen Stroke Centre with acute ischaemic stroke were included. The rate of
thrombolytic therapy in patients with migraine was compared to patients with no history of migraine. A multivariate analysis was
performed to adjust confounding factors. Results. A total of 170 young stroke patients were enrolled, 49 with migraine and 121 with
nomigraine. In total, 10.2% of young patients withmigraine received thrombolytic therapy, compared with 26.5% of young patients
with nomigraine (𝑃 = 0.02).Migraine was associatedwith a low rate of thrombolytic therapywhen adjusting for possible confound-
ing factors (OR 0.19 CI: 0.05–0.72, 𝑃 = 0.02). Conclusion. Migraine is associated with a low rate of thrombolytic therapy in young
patients admitted with acute ischaemic stroke. Migraine patients admitted with acute ischaemic stroke are at risk of maltreatment.
1. Introduction
Migraine is a common neurological disorder with a preva-
lence of approximately 6–15% inmales and 15–25% in females
[1–3]. While migraine is highly prevalent in young adults, the
incidence of ischaemic stroke is relatively low (6.6 to 11.4 in
100 000 people/year) [4, 5]. In an emergency setting, it may
be difficult to distinguish stroke from strokemimics (SM) [6].
The administration of tPA to patients with SM is safe [7, 8]. It
may thus be worse to refrain from treating an acute ischaemic
stroke patient with tPA under suspicion of stroke mimic than
to unnecessarily treat a stroke mimic with tPA.
Migraine aura is a common SM and may be misinter-
preted as an ischaemic event [6–9]. Conversely, migraine
patients can have ischaemic events which are misinterpreted
as SM. This matter is especially crucial in emergency sit-
uations where thrombolytic therapy may be withheld in
patientswith a history ofmigraine because the treating doctor
suspects SM and not ischaemic stroke.This problem is highly
relevant inmigraine patients since this patient group has been
associated with a higher risk of ischaemic stroke [10, 11]. In
this study, we aimed to examine the rate of thrombolytic
therapy in young stroke patients with andwithout a history of
migraine.Wehypothesised thatmigrainewould be associated
with a lower rate of thrombolytic therapy, suggesting that tPA
treatment may be withheld in acute ischaemic stroke (AIS)
patients with a history of migraine.
2. Methods
All stroke patients admitted to the Bergen stroke centre
between February 2006 and April 2013 were prospectively
registered in the NORSTROKE registry. AIS was defined
in accordance with the Baltimore-Washington Cooperative
Young Stroke Study Criteria comprising neurological deficits
lasting longer than 24 hours or transient ischemic attacks in
which computed tomography (CT) or magnetic resonance
imaging (MRI) showed infarction related to symptoms [12].
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In this retrospective analysis, patients with ischaemic stroke
below the age of 50 years were included. A structured
interview was performed by a neurologist during the hospital
stay and data regarding migraine was registered. Patients
were stratified inmigraine andno-migraine groups according
to migraine history. Baseline characteristics and definitive
diagnoses were validated before inclusion. Based on pre-
senting symptoms, patients were classified according to the
OxfordCommunity Stroke Project classification (OCSP) [13].
Information regarding headache and aura as part of the acute
symptomatology was not registered.
Six cerebrovascular risk factors were assessed according
to a predefined protocol: angina pectoris, myocardial infarc-
tion, intermittent claudication, diabetes mellitus, hyperten-
sion, and smoking. Angina pectoris, myocardial infarction,
and intermittent claudication were based on diagnoses made
before the index stroke. Diabetes mellitus was considered
present if the patient was on glucose-lowering treatment
by diet or medication. Hypertension was defined as anti-
hypertensive treatment before the index stroke. Smoking
was trichotomised in never, former, and current smoking.
Current smoking was present if the patient was smoking at
least one cigarette per day within 1 year before stroke onset.
A risk factor score representing the number of risk factors
present in each patient was given as 0, 1, 2, or >2.
2.1. Statistics. STATA 12.1 (StataCorp, College Station, TX)
was used for all analyses.
Student’s t-test was used for continuous variables, Wil-
coxon rank sum test was used for continuous variables
not normally distributed, and Chi-square test was used
for categorical variables. A logistic regression analysis with
tPA administration as a dependent variable was performed
in order to identify the association between a history of
migraine and chance of thrombolytic therapy. Analyses were
adjusted for potential confounders by stepwise backward
selection. A separate univariate analysis was performed in
patients admitted within 270 minutes after stroke onset, that
is, patients eligible for thrombolytic therapy, to investigate
the rate of tPA treatment in eligible patients in detail. To
investigate the impact of age, we performed an identical
logistic regression analysis including patients within the age
range of 50–80 years to see if migraine influenced the rate of
thrombolytic therapy in this older age group.
The significance level was set at 0.05.
3. Results
In total, 170 patients were included, 112 males and 58 females.
There were 49 patients in the migraine group and 121 patients
in the no-migraine group. Demographics are shown in
Table 1. Median age was 43.3 years (IQR: 34.0–46.4) in the
migraine group and 43.5 years (IQR: 34.4–46.4) in the no-
migraine group (𝑃 = 0.31). There were fewer smokers
(𝑃 = 0.02) and significantly fewer risk factors present in the
migraine group (𝑃 < 0.01). At time of admission, there was
no difference as to OCSP. The rate of MRI was similar in the
two groups. The percentages of patients admitted within the
therapeutic window among the migraine and no-migraine
group were 30.6% versus 40.5%, respectively (𝑃 = 0.62).
The median NIHSS score upon admission was 2 in both
the migraine (IQR: 0–8) and no-migraine group (IQR: 0–6,
𝑃 = 0.90). Clinical data and acute management upon
admission are shown in Table 2. In total, 10.2% of patients
in the migraine group received thrombolytic therapy versus
26.5% in the no-migraine group (𝑃 = 0.02). Logistic
regression analysis showed that a diagnosis of migraine (OR
0.19 CI: 0.05–0.72, 𝑃 = 0.02) and longer time from ictus to
admission (OR 0.91 CI: 0.83–0.98, 𝑃 = 0.03) were associated
with a lower rate of tPA treatment (Table 3).
Analysing only the 59 patients admitted within 270 min-
utes, that is, eligible for thrombolytic therapy, displayed a dif-
ference in rate of tPA treatment with 26.7% of patients in the
migraine group receiving therapy compared to 59.1% in the
no-migraine group (𝑃 = 0.03). One patient in the migraine
group and one patient in the no-migraine group could not
receive thrombolytic treatment due to elevated international
normalized ratio (INR) (𝑃 = 0.57). There was no significant
difference in MRI verification of AIS diagnosis (𝑃 = 0.16).
All patients in the migraine group had diffusion lesions on
MRI 24 h after admittance verifying the diagnosis of AIS, 4 of
the patients in the no-migraine group were not examined by
MRI, and 2 did not have diffusion lesions present, thus receiv-
ing a diagnosis of AIS on basis of symptoms persisting >24 h.
Logistic regression analysis on patients admitted within the
thrombolytic time window showed an association between
migraine and a low rate of thrombolytic therapy (OR 0.16
CI: 0.03–0.72, 𝑃 = 0.017). Total risk factor score, time from
ictus to admission, andNIHSS on admission did not affect the
rate of thrombolytic therapy (Table 3). In patients admitted
within the thrombolytic time window aged 50–80 years, no
association between migraine and tPA treatment was found.
Higher NIHSS on admission and shorter time from ictus to
admission were associated with tPA treatment (Table 4).
4. Discussion
This study shows a significantly lower rate of thrombolytic
therapy among young AIS patients with migraine as com-
pared with AIS patients with no migraine. The low rate of
thrombolytic therapy may result from misdiagnosing AIS
symptoms as migrainous phenomena in young patients with
migraine.This misdiagnosingmay be apparent only in young
patients due to the low incidence of stroke compared to the
relatively high incidence of migrainous attacks in this age
group [1, 4, 5]. The low rate may also be a result of doctors
being reluctant to treat young patients with migraine and
possible AIS because of the risk of intracerebral haemorrhage
(ICH) after tPA administration, especially if only mild AIS
symptoms are present. However, since administration of tPA
in SM patients is proven safe, this should not be a sole reason
to refrain from treating a possible AIS with tPA [7, 8]. The
fewer risk factors present in patients with migraine may
mislead the doctor, making a diagnosis of AIS appear less
likely, thereby supporting the theory of misdiagnosing. This
theory is also supported by the finding of no association
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Table 1: Demographic characteristics of young ischaemic stroke patients with and without migraine.
Migraine No-migraine
𝑃
𝑁 = 49 𝑁 = 121
Median age, years (IQR) 43.3 (34.0–46.4) 43.5 (38.0–46.4) 0.31
Male sex (%) 57.1 69.4 0.12
Smoking status (%) 0.03
Never smoked 55.1 40.2
Former smoker 24.5 17.9
Current smoker 20.4 41.9
Hypertension (%) 18.4 26.5 0.26
Diabetes (%) 6.1 6.7 0.90
Hypercholesterolemia (%) 4.1 10.2 0.13
Atrial fibrillation (%) 0 5.0 0.11
Prior VD (%) 8.1 12.6 0.41
Total risk factors (%) <0.01
0 69.4 37.2
1 18.4 43.8
2 8.2 12.4
>2 4.1 6.6
IQR: interquartile range; VD: vascular disease (defined as prior cerebrovascular disease, cardiovascular disease, or peripheral vascular disease).
Table 2: Clinical characteristics and initial management of young ischaemic stroke patients with and without migraine.
Migraine No-migraine
𝑃
𝑁 = 49 𝑁 = 121
Median NIHSS score (IQR) 2 (0–8) 2 (0–6) 0.90
Median ictus to admittance time (min., IQR) 191 (96–336) 135 (70–511) 0.55
Presenting symptomatology (OCSP) 0.75
LACI (%) 18.4 22.3
TACI (%) 8.2 10.7
PACI (%) 44.9 36.4
POCI (%) 28.6 30.6
Admitted < 270min after ictus (%) 30.6 40.5 0.86
CT-scan as initial imaging (%) 77.6 77.7 0.99
Receiving thrombolytic therapy (%) 10.2 26.5 0.02
NIHSS: National Institute of Health Stroke Scale; IQR: interquartile range; OCSP: Oxford Community Stroke Project Classification; LACI: lacunar infarct;
TACI: total anterior circulation infarct; PACI: partial anterior circulation infarct; POCI: posterior circulation infarct; CT: computed tomography.
between migraine and tPA treatment in patients aged 50–
80 years. Age is an important risk factor for stroke and
higher age will therefore increase the likelihood that stroke-
like symptoms are caused by AIS [14, 15].
Although migraine is more common in females, there
was a predominance of males in both the migraine and no-
migraine groups in our material; this is a result of the inclu-
sion criteria of acute ischaemic stroke in young adults, which
is a more frequent event in males than females. Migrainous
attacks are common with almost 14% of young adults experi-
encing a migrainous attack in one year [3]. A Danish study
investigating prevalence and incidence rates of migrainous
aura reported a 1–3 year prevalence of 4.1 and an incidence
rate of 5.6 per 1000 person-years [16]. This indicates that
migrainous aura may be a common phenomenon in young
adults, making the task of differentiating migraine aura from
AIS a frequent task for the doctor treating stroke patients.
The present study highlights that a correct diagnosis of
AIS is imperative to ensure that neither tPA treatment is
wrongly withheld from AIS patients on suspicion of SM nor
patients with SM are treated with tPA unnecessarily. Clinical
predictors for improved diagnostic accuracy have been iden-
tified, but their usefulness in clinical practice is uncertain [17,
18]. Increased use of imagingmodalities such as CT perfusion
or MR diffusion weighted imaging in the emergency depart-
ment can improve the diagnostic accuracy and minimise
the risk of clinical misinterpretation of AIS and possible
maltreatment of young patients with migraine [18–20].
There are some limitations in this study.The sample size is
relatively small, even after 6 years of inclusion. Secondly, since
only hospitalized AIS patients were eligible for inclusion,
patients with possible AIS not admitted to the hospital were
therefore not included in our study; this could be a source of
selection bias. However, the Bergen Stroke Centre enforces
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Table 3: Logistic regression analysis displaying factors associated with thrombolytic therapy (rTPA) in all young AIS patients and young AIS
patients admitted within the thrombolytic time window.
All patients Admitted within 270min
OR 95% CI 𝑃 OR 95% CI 𝑃
Migraine 0.19 0.05–0.72 0.02 0.16 0.04–0.72 0.02
Time from ictus to admission in hours 0.90 0.83–0.98 0.02 0.94 0.84–1.06 0.32
NIHSS on admission 1.09 0.99–1.18 0.05 1.07 0.97–1.17 0.17
Total risk factor score 0.56 0.27–1.17 0.12 0.47 0.19–1.13 0.09
AIS: acute ischaemic stroke; NIHSS: National Institutes of Health Stroke Scale; OR: odds ratio; CI: confidence interval.
There was an association between migraine and a low rate of received rTPA treatment in young patients with acute ischaemic stroke.
Table 4: Logistic regression analysis displaying factors associated with thrombolytic therapy (tPA) in AIS patients admitted within the
thrombolytic time window between 50 and 80 years of age.
OR 95% CI 𝑃
Migraine 1.48 0.84–2.61 0.17
Time from ictus to admission in hours 0.92 0.86–0.97 <0.01
NIHSS on admission 1.07 1.13–1.25 <0.01
Total risk factor score 0.94 0.74–1.17 0.57
AIS: acute ischaemic stroke; NIHSS: National Institutes of Health Stroke Scale; OR: odds ratio; CI: confidence interval.
There was an association between shorter time from ictus to admission, higher NIHSS on admission, and high rate of rTPA treatment in acute ischaemic stroke
patients between 50 and 80 years of age.
a zero threshold for admitting patients with symptoms
indicating stroke; we therefore believe that the vast majority
of patients were admitted and therefore eligible for inclusion.
This is supported by the low median NIHSS scores. The low
NIHSS scores also indicate that small ischaemic strokes with
minor deficits are included; this can however not explain the
observed low rate of treatment in patients withmigraine since
these minor strokes are equally distributed between the two
groups. There was neither a significant difference in stroke
severity as toNIHSS on admissionwhen comparingmigraine
and no-migraine patients receiving tPA nor was there any
difference when comparing the migraine and no-migraine
patients not receiving tPA.
In conclusion, migraine is associated with a low rate of
thrombolytic therapy in young patients admitted with acute
ischaemic stroke. Migraine patients with acute ischaemic
stroke may therefore run the risk of maltreatment and poor
clinical outcome.
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